Axios
Novavax says COVID-19 vaccine was 90% effective in Phase 3 trial, including against variants
Novavax, a Maryland biotechnology company, announced Monday that its COVID-19 vaccine was 90.4% effective in its Phase 3 trial, including against coronavirus variants.Why it matters: The study of 29,960 participants in the U.S. and Mexico found the shot was safe and highly effective, paving the way for the FDA to clear a 4th vaccine for emergency use by the end of the year.Get market news worthy of your time with Axios Markets. Subscribe for free.Between the lines: Because the U.S. is currently